Sanofi (NASDAQ:SNY) Shares Sold by Cullen Capital Management LLC

Cullen Capital Management LLC cut its stake in Sanofi (NASDAQ:SNY) by 10.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 261,112 shares of the company’s stock after selling 29,423 shares during the period. Cullen Capital Management LLC’s holdings in Sanofi were worth $12,593,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new position in shares of Sanofi in the 4th quarter valued at $25,000. McClarren Financial Advisors Inc. boosted its holdings in Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the last quarter. Lee Danner & Bass Inc. purchased a new stake in Sanofi during the fourth quarter valued at about $31,000. Sunbelt Securities Inc. increased its stake in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the last quarter. Finally, Sierra Ocean LLC purchased a new position in shares of Sanofi in the 4th quarter worth about $44,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Sanofi stock opened at $51.98 on Friday. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company has a market capitalization of $131.92 billion, a price-to-earnings ratio of 20.88, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The firm’s fifty day moving average price is $55.37 and its 200 day moving average price is $52.71.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SNY. The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday, March 21st. They set a “neutral” rating and a $65.00 target price for the company. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $62.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.